Drug interactions
Brexucabtagene autoleucel + Carboplatin
Severity: Major
Brexucabtagene autoleucel and Carboplatin: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Carboplatin may reduce the expansion and persistence of CAR T cells through lymphotoxic and myelosuppressive effects. It also adds to infection risk after cell therapy.
What this interaction means in plain words
Brexucabtagene autoleucel and Carboplatin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Brexucabtagene autoleucel belongs to Oncology; Carboplatin belongs to Oncology.
Why it happens
Additive immunosuppressive and myelosuppressive effects that may impair CAR T-cell function.
What to do
Avoid non-lymphodepleting chemotherapy around leukapheresis and infusion. Monitor blood counts and for infection if chemotherapy is required.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Brexucabtagene autoleucel and Carboplatin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Carboplatin
Other interactions of Brexucabtagene autoleucel
Frequently asked questions
Can I take Brexucabtagene autoleucel with Carboplatin?
MediHelp rates the interaction as major. Brexucabtagene autoleucel and Carboplatin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Carboplatin may reduce the expansion and persistence of CAR T cells through lymphotoxic and myelosuppressive effects. It also adds to infection risk after cell therapy.
How serious is the interaction between Brexucabtagene autoleucel and Carboplatin?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid non-lymphodepleting chemotherapy around leukapheresis and infusion. Monitor blood counts and for infection if chemotherapy is required.
What other medicines interact with Carboplatin?
MediHelp also lists interactions of Carboplatin with, for example, Adenovirus types 4 and 7 live, Amikacin, Amphotericin b deoxycholate. The full list is on the Carboplatin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
